Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndromes: early-phase trial registry
73 of 193 indexed Myelodysplastic Syndromes trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #55 of 28,707 conditions by registered trial count.
193 US clinical trials · 73 currently recruiting · #55 of 28,707 conditions by registered trial count
Myelodysplastic Syndromes: 193 US clinical trials tracked, 73 recruiting.
Myelodysplastic Syndromes is the subject of 193 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 13 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndromes
OPEN 73 | RECR 38% | LATE 11 | EARLY 148 | RANK #55 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Sclerosis (38% recruiting · 317 trials)
Myelodysplastic Syndromes lists 73 open slots (38% of 193 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndromes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndromes recruits in line with its size-band peers.
73 of 193 indexed trials (37.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myelodysplastic Syndromes trials is spread across many organizations.
Washington University School of Medicine accounts for 13 of 193 trials (6.7%). 98 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic Syndromes trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 174 trials that report a genuine target (sentinel values excluded). 118 of those (67.8%) plan for fewer than 100 participants.
-
Myelodysplastic Syndromes research is mostly interventional.
177 interventional and 16 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
193 total, page 3 of 4
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT03912064
NTX-301 in MDS/AML
University of Alabama at Birmingham
NCT04167917
Inqovi Maintenance Therapy in Myeloid Neoplasms
Massachusetts General Hospital
NCT04980404
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Washington University School of Medicine
NCT03572764
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT05455294
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
NCT03843528
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
H. Lee Moffitt Cancer Center and Research Institute
NCT04798339
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Case Comprehensive Cancer Center
NCT04668885
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT02477878
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Baylor College of Medicine
NCT05236764
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
SWOG Cancer Research Network
NCT00919425
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
City of Hope Medical Center
NCT00964821
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
NCT00003816
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Children's Oncology Group
NCT00003593
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
NCT02775903
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center
NCT00782145
A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome
National Institutes of Health Clinical Center (CC)
NCT00001839
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Taiho Oncology
NCT03502668
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
SWOG Cancer Research Network
NCT00016419
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Millennium Pharmaceuticals
NCT02610777
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
Notable Labs
NCT04014764
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
Eastern Cooperative Oncology Group
NCT00003138
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Washington University School of Medicine
NCT01687400
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
NCT00607997
Topotecan in Treating Patients With Myelodysplastic Syndrome
Alliance for Clinical Trials in Oncology
NCT00003675
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
NCT00241358
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
Center for International Blood and Marrow Transplant Research
NCT03558386
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
Roswell Park Cancer Institute
NCT00003662
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Alliance for Clinical Trials in Oncology
NCT00053196
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Sunesis Pharmaceuticals
NCT00246662
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme
NCT00086125
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03755414
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Aileron Therapeutics
NCT02909972
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Ascorbic Acid Levels in MDS, AML, and CMML Patients
Van Andel Research Institute
NCT03526666
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
NCT01164163
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
NCT03176849
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
NCT00003398
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT00602693
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT00534118
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
Genzyme, a Sanofi Company
NCT00531232
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
NCT00423514
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Washington University School of Medicine
NCT01913951
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Case Comprehensive Cancer Center
NCT00054327
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Janssen Research & Development
NCT03011034
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 68 |
| Phase 3 | 9 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndromes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndromes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndromes page
193 registered trials, 73 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 73 Myelodysplastic Syndromes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Myelodysplastic Syndromes trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndromes condition card totals 193 registered trials; most-linked intervention Azacitidine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.